Naivek Presents Fibrosis Treatment Research Results at the World’s Most Prestigious 'Keystone Symposia' Conference

[Asia Economy Reporter Jang Hyowon] The global fibrosis treatment market is rapidly growing, expected to reach approximately $47 billion (54 trillion KRW) by 2025. In this context, Naivek announced on the 9th that it will present research results on its fibrosis-related pipeline at the world’s most prestigious ‘Keystone Symposia’ conference.

Peptide fusion bio-specialist company Naivek revealed on the 9th that it will present research outcomes related to inflammation and fibrosis, including treatments for non-alcoholic steatohepatitis (NIPEP-NASH) and pulmonary fibrosis (NIPEP-PF), at the globally renowned life sciences conference ‘Keystone Symposia.’ Naivek has been invited to attend the Keystone Symposia for the second consecutive year following last year.

The Keystone Symposia, held from the 12th to the 16th, is an international conference boasting the highest authority in the fields of cancer drug development, genetics, and molecular biology. Naivek is scheduled to present in the session titled ‘TISSUE FIBROSIS AND REPAIR: MECHANISMS, HUMAN DISEASE AND THERAPIES,’ where it will share its research results related to fibrosis, including pulmonary fibrosis and liver fibrosis.

Naivek’s ‘NIPEP-NASH’ effectively inhibits biomarkers that uniquely increase in ‘NASH (non-alcoholic steatohepatitis)’ and ‘NAFLD (non-alcoholic fatty liver disease),’ reducing liver tissue inflammation and fat accumulation, as well as eliminating fibrosis.

Additionally, the pulmonary fibrosis treatment (NIPEP-PF), currently undergoing a global Phase 1 clinical trial in Australia, operates via a completely different mechanism from existing fibrosis treatments. It directly binds to receptors involved in the overexpression of inflammation in lung tissue, fundamentally blocking excessive collagen production. This results in the restoration of normal lung tissue.

A Naivek representative stated, “At this Keystone Symposia, we plan to share introductions to NIPEP-NASH and NIPEP-PF, animal efficacy study results to date, and current progress.” They added, “We will also conduct in-depth discussions regarding additional joint research and development or technology transfers with global big pharma companies.”

This content was produced with the assistance of AI translation services.